Less than 2 months after BARDA spearheaded US efforts to ensure a large supply of vaccine to fight Covid-19 with a $628 million alliance with Emergent BioSolutions, AstraZeneca has stepped up with a new, $174 million add-on contract for its CDMO operation to produce their Oxford vaccine at scale in Emergent’s Baltimore facility.
AstraZeneca promised it could deliver 2 billion doses of their vaccine to the world next year, making it one of the leading players in the drive to inoculate the world against Covid-19. This new contract development and commercialization pact builds on their initial $87 million contract regarding AZD1222, which they signed in June.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 85,800+ biopharma pros reading Endpoints daily — and it's free.
Business - Latest - Google News
July 27, 2020 at 10:17PM
https://ift.tt/32ZgsbP
Moderna begins first US pivotal Covid-19 vaccine study, lands $472M more from BARDA - Endpoints News
Business - Latest - Google News
https://ift.tt/2Rx7A4Y
Bagikan Berita Ini
0 Response to "Moderna begins first US pivotal Covid-19 vaccine study, lands $472M more from BARDA - Endpoints News"
Post a Comment